Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Schnitzler Syndrome
NCT01245127Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- May 2011
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in Schnitzler syndrome, sponsored by UZ Leuven. Started May 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NCT01245127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245127.